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Abstract
Background: High risk medications are commonly prescribed to older US patients. Currently, less is known about
high risk medication prescribing in other Western Countries, including the UK. We measured trends and correlates
of high risk medication prescribing in a subset of the older UK population (community/institutionalized) to inform
harm minimization efforts.
Methods: Three cross-sectional samples from primary care electronic clinical records (UK Clinical Practice Research
Datalink, CPRD) in fiscal years 2003/04, 2007/08 and 2011/12 were taken. This yielded a sample of 13,900 people aged
65 years or over from 504 UK general practices. High risk medications were defined by 2012 Beers Criteria adapted for
the UK. Using descriptive statistical methods and regression modelling, prevalence of ‘any’ (drugs prescribed at least
once per year) and ‘long-term’ (drugs prescribed all quarters of year) high risk medication prescribing and correlates
were determined.
Results: While polypharmacy rates have risen sharply, high risk medication prevalence has remained stable across a
decade. A third of older (65+) people are exposed to high risk medications, but only half of the total prevalence was
long-term (any = 38.4 % [95 % CI: 36.3, 40.5]; long-term = 17.4 % [15.9, 19.9] in 2011/12). Long-term but not any high
risk medication exposure was associated with older ages (85 years or over). Women and people with higher
polypharmacy burden were at greater risk of exposure; lower socio-economic status was not associated. Ten
drugs/drug classes accounted for most of high risk medication prescribing in 2011/12.
Conclusions: High risk medication prescribing has not increased over time against a background of increasing
polypharmacy in the UK. Half of patients receiving high risk medications do so for less than a year. Reducing or
optimising the use of a limited number of drugs could dramatically reduce high risk medications in older people.
Further research is needed to investigate why the oldest old and women are at greater risk. Interventions to
reduce high risk medications may need to target shorter and long-term use separately.
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Background
Polypharmacy, the use of multiple drugs by the same indi-
vidual [1, 2], is increasingly common in older people in
both the United States (US) [3] and United Kingdom
(UK) [4].
Over the past decade, the average number of pre-
scribed items per person per year in England rose from
12.4 in 2002 to 18.7 in 2012; patients aged 60 years or
over received half of all prescribed items [4]. Any medi-
cine has the potential for benefits as well as risks [5, 6],
but older people are at greater risk of adverse reactions
because of age-associated changes affecting pharmaco-
kinetics and pharmacodynamics [7].
Various tools [5, 8], including the START/STOPP tool-
kit [9] and the Beers Criteria [10–12], have been created
to help clinicians to minimise risk by avoiding the use of
drugs with a higher risk-to-benefit ratio in older people.
Although historically, it has been proposed that Beers
criteria have weaknesses when used in European clinical
settings [13], recently it has shown the Beers criteria to
be more sensitive and complementary to tools developed
for use in Europe (e.g. STOPP) [13, 14]. The Beers Cri-
teria is endorsed by the American Geriatrics Society and
their recommendations have recently been updated
through systematic review of the evidence base. Beers
lists drugs (or drug classes) with potentially harmful ef-
fects in the older population, including those consistently
associated with poor patient outcomes (adverse drug reac-
tions, hospitalisation, and mortality) [12]. To develop the
2012 update, a multidisciplinary panel of experts used a
modified Delphi method to select drugs (or drug classes)
with a potentially high risk-to-benefit ratio in older people
and to reach consensus on their safest use, including ex-
plicit recommendations regarding drugs to avoid in all or
selected circumstances. Aside from clinical use, the Beers
Criteria have been used extensively in epidemiological
studies, and implemented in healthcare settings to assess
the quality of care [8, 15]. In the US, the National Com-
mittee for Quality Assurance (NCQA) has used the Beers
Criteria as one of the main criteria to define the list of
high risk medications (HRM) to avoid in the elderly. Based
on the NCQA list, approximately a quarter of the US
older population received at least one HRM in 2006 and
2007 [16, 17].
Estimating the burden of HRM, patterns, and appro-
priateness of their prescribing is essential to develop ef-
fective strategies for improving drug safety both in the
UK and in other healthcare systems worldwide [18]. UK
cross-sectional research [19, 20] has identified that in-
creased number of drugs prescribed is consistently associ-
ated with greater exposure to potentially inappropriate
prescribing; however it remains unknown whether the re-
cent increases in prescribing rates are mirrored by a con-
comitant increase in harmful prescribing. Moreover, to the
best of our knowledge, while exposure to at least one
HRM (‘any exposure’) has always been the object of re-
search, regular exposure to high risk medicines (‘long term
exposure’) has not been investigated.
We investigated the current burden, trends and corre-
lates of both any and long-term receipt of HRM using
the 2012 Beers Criteria (adapted for the UK) in UK older
patients in general practice. We also assessed the clinical
conditions most frequently associated with HRM use
and the appropriateness of HRM use according to Beers
recommendations in 2011/12 patient records.
Methods
Cohort identification
We used a sample of patients registered with UK general
practices contributing data to the Clinical Practice Research
Datalink (CPRD) [21] GOLD version (available on July
2012). The protocol, including this and other research pro-
jects, was designed to investigate the health and prescribing
burden of the oldest old over time in the UK by comparing
this section of the population with younger age groups. The
sampling procedure has been described elsewhere [22].
Briefly, to maximise the number of people with extreme
ages in our dataset, we started by selecting centenarians
registered at any time with general practices contributing to
CPRD. Each centenarian (100 or over) was randomly
matched (one to one for females, one to two for males) to
younger patients aged 65 years or over, by practice, gender
and calendar year in each of six younger age-groups (strati-
fied by 5-10 year age bands) in order to have adequate
number of younger patients in the control groups.
From the pool of 50,313 patients sampled, we initially
drew a sub-sample of 21,377 patients including all sub-
jects who turned 100 in the calendar years 2002/3, 2006/7,
and 2010/11 and their matched pair. To account for po-
tential end-of-life prescription changes, the 14,578 pa-
tients registered with the practice for the entire year were
selected; thirty-one patients with uncertain date of death
(discrepancy between CPRD and Office of National Statis-
tics data) and 408 patients who died within three months
after the end of each sampled year were also excluded. Fi-
nally, 239 patients with no clinical or therapy records at
all for the three years prior to the sampled year were ex-
cluded as age-standardised rates of consulting behaviour
in UK general practice [23] suggest that such individuals
are ‘non-active’ (i.e. uncertain vital status).
Prescribing patterns were investigated for the three fiscal
years (1st April through 31st March), noting that each sub-
ject contributed only to one of the three year groups. Due
to the complexity of computing prescribing data, and for
clarity of reporting we restricted our analysis to: 2011/12,
the most recent year with complete data available; 2003/4,
the year of publication of the previous revision of the Beers
criteria [11] that coincided with widespread adoption of
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electronic medication coding in the UK; and 2007/8, an
equidistant, intermediate time point between the previ-
ous two.
Study measures
We extracted age categorised into age groups (65–84
years and 85+ years), sex (male, female), and as a proxy of
socio-economic status we obtained quintiles of the Index
of Multiple Deprivation (IMD, 2010) for England for those
patients whose general practices had consented for patient
postcodes to be linked to socio-economic data.
We included only prescription data for drugs with
predominantly systemic effect (oral, sub-lingual, rectal,
subcutaneous, intramuscular, intravenous route, or
trans-dermal patch). Over-the-counter medicines were
excluded as they are not routinely recorded in general
practice records.
For each year, for each person we calculated the total
number of drugs and HRM prescribed (i.e. at least once
that year) to derive ‘any’ medication count. We then iden-
tified drugs or HRM that were prescribed for all quarters
of the given year, as a proxy of ‘long-term’ prescribing.
We defined HRM using the 2012 Beers’ criteria, a list of
53 medications or medication classes potentially harmful
in the older population [12]. We focused on the 34 drugs
or drug classes defined as ‘drugs to avoid in older adults’.
This group included a sub-group of drugs to be avoided
only if an additional filtering condition (i.e. a Beers recom-
mendation) was met (e.g. ‘alpha-blockers to be avoided
only if used as anti-hypertensive drugs’). When analysing
trends and main correlates, we reported the prevalence of
HRM irrespective of whether the additional filter (if any)
was present. To accommodate differences between the US
and UK drug availability, two pharmacists and two geriatri-
cians independently reviewed the drugs lists to identify
modifications, in line with the British National Formulary
[24]. The results were discussed and consensus reached: 47
drugs that are not available as UK-licensed prescription-
only products were removed and the final list of 92 drugs
(see Additional file 1) including five drugs substituted for
their UK equivalents, and seven drugs (all benzodiaze-
pines) added after checking whether any other extra
substance (other than those included in the US) were
included in the UK formulary (particularly historic
preparations) (Additional file 1). Insulin was excluded
because the sliding scale prescribing pattern could not
be operationalised.
To document the appropriateness of their use in 2011/
12, the additional filter (Beers recommendations) was
applied to HRM prescribed to 1 % or more of the popu-
lation. The methods used to operationalise the Beers
recommendations are reported in Additional file 2.
For each year the prescribing burden of HRM (any or
long-term) was assessed. To ensure adequate numbers
contributed to analysis, we categorised measures of
any HRM into four categories (none, one, two or three
or more drugs) and long-term prescribing into three
levels (none, one or two or more drugs). Drugs preva-
lence was assessed at the mid-point of the year 2011/
12 (30th September).
Multimorbidity was operationalised as the count of
15 chronic diseases included in previous research in
UK general practice [25, 26]: hypertension, atrial fibril-
lation, coronary heart disease, chronic heart failure,
stroke/transient ischaemic attack, cancer, chronic kid-
ney disease [any stage], asthma, chronic obstructive
pulmonary disease, dementia, depression, mental health
disorders [psychoses, schizophrenia, bipolar affective
disease], diabetes, hypothyroidism, and epilepsy).
Three common disabling conditions of ageing (osteo-
arthritis, osteoporosis and anaemia) were also categorised.
The resultant multimorbidity index (range 0–18) was
assessed at the mid-point of the fiscal year 2011/12 and
further categorised (none, one to two, and three or more).
Statistical analysis
To account for differences in population structure be-
tween 2003/4 and 2011/12 all estimates were weighted
to the UK 2011 population composition (in five year age
groups for men and women separately) based on the UK
Office of National Statistics (ONS) data [27]. Data were
reported as weighted percentages and variables com-
pared using design-based chi-square tests.
Combining data from all three samples, we undertook
multivariable logistic regression analyses (accounting for
study design), to test the association between the outcome
(i.e. any HRM exposure - none versus one or more HRM)
and potential explanatory variables. Three models were
developed for these analyses, adding progressively more
covariates at each step (Model 1 = year sampled, age, gen-
der; Model 2 =Model 1 plus medication count; and Model
3 =Model 2 plus multimorbidity and socio-economic sta-
tus). The same modelling procedures were used for the
modelling ‘long-term’ HRM (none versus one or more
long-term HRM). Weighted and adjusted odds ratios and
associated 95 % confidence intervals are presented for
each model. Models were scrutinised for multicollinearity
by reviewing the variance inflation factors. We also ex-
plored potential interactions between time (year sampled)
and each explanatory variable on our outcome measures.
Weighted and adjusted odds ratios and associated 95 %
confidence intervals are presented for each model.
Additional analysis was undertaken in data restricted to
the 2011/12 sample. Here we explored the associations be-
tween different medical conditions and HRM exposure
(any or long-term), in multivariable models including
dummy variables for the 18 individual chronic conditions
and all other explanatory variables.
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A conservative alpha level of 0.01 was chosen as the
threshold for statistical significance.
Data were analysed using the Stata 13 (StataCorp.
2013. Stata Statistical Software: Release 13. College Sta-
tion, TX: StataCorp LP).
Ethics
The CPRD has been granted Multiple Research Ethics
Committee approval (NRES Committee East Midlands –
Derby, reference 05/MRE04/87) to undertake purely ob-
servational studies, with external data linkages including
Hospital Episode Statistics and Office for National Sta-
tistics mortality data. The work of CPRD is also covered
by NIGB-ECC approval ECC 5-05 (a) 2012. The present
study was based on anonymised CPRD data used for ob-
servational research purposes. The study protocol was
reviewed and approved by the Independent Scientific
Advisory Committee (ISAC) for the UK Medicines and
Healthcare products Regulatory Agency (protocol ap-
proved 12_017A3). While ISAC is primarily responsible
for reviewing protocols for scientific quality, whenever
study-specific ethical issues arise, it may recommend
further ethical approval. In the case of this observational
research no further ethics scrutiny was deemed neces-
sary by ISAC.
Results
The studied sample comprised 13,900 people registered
with 504 UK general practices. Patients were broadly
similar across time, in terms of age, gender and socio-
economic status, although the proportions with no
major chronic diseases decreased between 2003/4 and
2011/12 (Table 1).
Medication counts significantly increased over time for
any and long-term prescribing (Table 1). The proportion
of patients receiving any ten or more drugs increased
(16.4 % to 24.6 %; p < 0.001) and a similar pattern was ob-
served for long-term prescribing (1.3 % to 3.8 %; p <
0.001). In contrast, the prevalence of any HRM remained
stable over time (2003/4: 38.7 %, 95 % CI 36.4 to 41.1 %;
20007/8: 36.9 %, 34.9 % to 39.0 %; 2011/12: 38.4 %, 36.3 to
40.5; p = 0.468). The prevalence of long-term use of HRM
was also stable (2003/4: 18.5 %, 95 % CI 16.8 to 20.3;
20007/8: 17.7 %, 16.3 % to 19.2 %; 2011/12: 17.4 %, 15.9 to
19.9; p = 0.609) accounting for approximately half of the
any HRM prescribing burden. Additional file 3 summa-
rises the percentages of people prescribed individual
HRMs for each year.
After adjusting for age and gender (Table 2, Model 1),
there was no difference in the risk of any HRM exposure
among the three sample years. When the rising medication
count was included (Model 2), the adjusted risk of HRM
exposure was lower in 2007/08 and 2011/12 compared
with 2003/04. Increased multimorbidity burden (Model 3)
was protective, while female sex and higher medication
counts conferred a greater risk of HRM. Oldest age was
not associated with any HRM. Overall, similar results were
found when we analysed the risk of long-term HRM
(Table 3), with the notable exception of oldest age, which
was now associated with greater risk of long-term HRM
(OR: 1.16; 95 % CI 1.04, 1.28; p = 0.007). There was no
evidence of multicollinearity in any models. No evi-
dence of statistical interactions between the year sam-
pled and other explanatory variables were observed,
suggesting that the underlying associations between the
correlates (sex, medication count, and multimorbidity)
and HRM remained consistent across the different
sampling years (data not presented).
We then restricted analysis to the most recent patient
sample from 2011/12. Accounting for confounders in-
cluding age, gender, number of drugs, Index of Multiple
Deprivation and all individual chronic conditions in-
cluded in the multimorbidity count (see above), patients
with osteoarthritis were at higher risk of any HRM,
while those with atrial fibrillation were at increased risk
of long-term HRM (Additional file 4). Patients with car-
diovascular risk factors or cardiovascular disease (dia-
betes, hypertension, coronary heart disease, and stroke/
transient ischaemic attack) were at reduced risk of any
or long-term HRM. (See Additional file 5 for the un-
adjusted weighted prevalence of any or long-term HRM
for all 18 clinical conditions).
We then explored any HRM exposure that was prevalent
in at least 1 % of the population (Fig. 1) in 2011/12. Overall,
the ten drugs included in this subgroup accounted for 85 %
of all patients prescribed a HRM. The latter included non-
steroidal anti-inflammatory drugs (NSAIDs) (13.8 % of pa-
tients; mainly ibuprofen/naproxen), benzodiazepines (7.8 %;
mostly temazepam/diazepam), amitriptyline (6.4 %), doxa-
zosin (4.8 %), zopliclone (4.1 %), nitrofurantoin (4.0 %),
chlorphenamine (1.4 %), hyoscine (1.2 %) metoclopramide
(1.1 %) and oestrogens (1.0 %). Although the rates were
lower, a similar pattern of use was observed for long-term
HRM with the exception of nitrofurantoin whose preva-
lence was negligible (Additional file 3). When Beers rec-
ommendations were applied, amitriptyline emerged as
the most prevalent potentially inappropriate medication
(6.4 %), followed by benzodiazepines (4.9 %), doxazosin
(4.4 %); the rate for NSAIDs had dropped considerably
(3.1 %) (Fig. 1).
Discussion
We present the first UK primary care data on the preva-
lence, trends over time, correlates and appropriateness
of high risk medication prescribing in older people using
the updated 2012 Beers Criteria adapted for the UK. The
proportion of older people exposed to HRM remained
constant across time against a background of increasing
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polypharmacy burden. While a third of older people are
exposed to HRM, only half of them receive HRM pre-
scriptions over the long-term. Drug burden and female
sex were associated with any and long-term HRM, but old-
est age (85 years or older) was only correlated with long-
term HRM use. No association with socio-economic status
was found. Patients with osteoarthritis and atrial fibrillation
were at greater risk of HRM, while the presence of cardio-
vascular risk factors or cardiovascular disease was associ-
ated with lower risk. Ten drugs/drug classes accounted for
almost all HRM prescribing in 2011/12.
Direct comparisons between our results and previous UK
findings are also difficult due to differences in definitions
and methodology. Our definition of HRM is conceptually
similar with the Beers 2003 version [11] of “potentially in-
appropriate medications” (PIMs), where few explicit filter-
ing recommendations were made. Three UK studies
applying the 2003 Beers criteria to general practice records
estimated the proportions of patients receiving any PIM at
32.2 % in 2003 [28], and 28.3 % [28] and 31.0 % [19] in
2005/6. These figures are similar, although somewhat lower
than our estimates.
We found that patients sampled in later years were at a
slightly reduced statistical risk of HRM exposure compared
with people registered in 2003/4. The observed risk reduc-
tion may be due to concomitant increase in non-HRM
drug prescribing rather than a change in HRM prescribing
over time. Previous research has found that people aged 85
Table 1 Characteristics of the study sample by year
Fiscal year
2003/4 2007/8 2011/12 p-value
Sample size (unweighted) 3882 4756 5262
Weighted % (95 % CI) Weighted % (95 % CI) Weighted % (95 % CI)
Age 0.862
65 to 84 years 86.6 (86.0, 87.2) 86.6 (86.0, 87.1) 86.4 (86.0, 86.8)
85 years or over 13.4 (12.8, 14.0) 13.4 (12.9, 14.0) 13.6 (13.2, 14.0)
Sex 0.997
Women 56.0 (50.9, 61.0) 55.8 (51.5, 59.9) 55.8 (51.4, 60.2)
Socio-economic status (index of multiple deprivation quintile) 0.430
Least deprived quintile 15.9 (12.7, 19.7) 17.8 (14.3, 22.0) 20.0 (16.8, 23.6)
2nd quintile 16.0 (13.5, 18.9) 18.7 (16.3, 21.3) 16.6 (14.4, 19.2)
3rd quintile 14.2 (11.9, 16.7) 13.3 (11.1, 15.7) 13.2 (10.6, 16.4)
4th quintile 12.6 (9.9, 15.9) 10.5 (8.3, 13.2) 9.4 (7.7, 11.4)
Most deprived quintile 8.4 (6.2, 11.2) 8.2 (6.5, 10.3) 6.0 (4.6, 7.7)
Missing (no linkage) 33.0 (27.4, 39.0) 31.6 (26.7, 37.0) 34.7 (29.3, 40.6)
Multimorbidity (number of chronic conditions) <0.001
0 21.9 (19.5, 24.6) 18.7 (16.9, 20.8) 16.6 (14.9, 18.3)
1 to 2 50.1 (47.5, 52.8) 46.9 (44.5, 49.2) 46.4 (44.3, 48.5)
3 or more 27.9 (25.8, 30.2) 34.4 (32.3, 36.6) 37.0 (35.0, 39.2)
Medications count (number of drugs prescribed at
least once during the year)
<0.001
0 12.2 (10.5, 14.0) 9.7 (8.4, 11.3) 7.8 (6.6, 9.2)
1 8.7 (7.4, 10.2) 7.1 (6.0, 8.4) 5.9 (4.9, 7.0)
2 to 4 26.9 (24.8, 29.2) 25.3 (23.4, 27.3) 25.7 (23.8, 27.6)
5 to 9 35.8 (33.5, 38.0) 36.6 (34.7, 38.5) 36.1 (34.0, 38.2)
10 or more 16.4 (14.7, 18.3) 21.2 (19.6, 23.0) 24.6 (22.8, 26.5)
Medications count (number of drugs prescribed all quarters) <0.001
0 33.9 (31.5, 36.4) 26.5 (24.5, 28.5) 21.7 (19.8, 23.8)
1 14.0 (12.5, 15.8) 12.8 (11.5, 14.4) 12.3 (10.9, 13.7)
2 to 4 35.6 (33.3, 37.9) 35.7 (33.9, 37.5) 37.1 (35.0, 39.2)
5 to 9 15.1 (13.6, 16.8) 23.2 (21.6, 24.9) 25.2 (23.3, 27.0)
10 or more 1.3 (0.8, 2.2) 1.8 (1.4, 2.4) 3.8 (3.1, 4.6)
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and older are less likely to receive one or more HRM per
year [16, 29]. Similarly, we found that, accounting for con-
founders, older age (85 years and over) was associated with
lower risk of ‘any’ HRM exposure, even though this result
did not reach our pre-defined level of statistical signifi-
cance (OR: 0.90, 95 % CI: 0.82, 0.99; p = 0.033). Conversely,
the oldest old were at increased risk of continuous HRM
exposure. The fact that people aged 85 and older, the most
vulnerable section of the older population, are at greater
risk of long-term HRM is somehow concerning. To the
best of our knowledge this finding has not been previously
reported and would merit further investigation. These data
suggest that, in older people, shorter and long-term
HRM exposure need to be investigated separately and
interventions to reduce HRM may need to target both
shorter and long-term use. Consistent with previous re-
ports, we found being female, and taking increasing
numbers of concomitant medications are strongly asso-
ciated with the risk of PIMs exposure [19, 20]. While
socio-economic status was found to be weakly associ-
ated in previous UK [19] and in the US reports [16], we
observed no such effect.
Our finding that increased multimorbidity index was
protective of HRM exposure requires careful consideration
and might be the effect of confounding by indication.
When the four cardiovascular conditions (hypertension,
diabetes, coronary heart disease, stroke/transient ischaemic
attack) were excluded, the index was no longer associated
with HRM risk (data not shown). This may be due to po-
tential confounding as QOF cardiovascular conditions may
be subject to enhanced monitoring; in addition, NSAIDs
and amitriptyline both have explicit notes regarding cau-
tionary prescribing in patients with cardiovascular risk.
Patients with osteoarthritis and atrial fibrillation were at
Table 2 Logistic regression models for any HRM prescribing
Model 1 Model 2 Model 3
Sample size (unweighted)a 12,532 12,532 12,532
Weighted OR (95 % CI) p-value Weighted OR (95 % CI) p-value Weighted OR (95 % CI) p-value
Year sampled
2003/4 1 1 1
2007/8 0.88 (0.76, 1.00) 0.059 0.77 (0.67, 0.89) <0.001 0.78 (0.67, 0.90) 0.001
2011/12 0.91 (0.79, 1.03) 0.157 0.76 (0.65, 0.87) <0.001 0.76 (0.65, 0.87) <0.001
Age
65 to 84 years 1 1 1
85 years or over 1.06 (0.97, 1.16) 0.175 0.89 (0.81, 0.97) 0.012 0.90 (0.82, 0.99) 0.033
Sex
Men 1 1 1
Women 1.28 (1.13, 1.43) <0.001 1.18 (1.04, 1.33) 0.007 1.18 (1.04, 1.33) 0.008
Medications count (number of drugs)
1 1 1
2 to 4 3.16 (2.22, 4.49) <0.001 3.66 (2.57, 5.20) <0.001
5 to 9 6.46 (4.54, 9.18) <0.001 8.44 (5.92, 12.0) <0.001
10 or more 18.23 (12.7, 26.0) <0.001 25.46 (17.7, 36.5) <0.001
Multimorbidity (number of diseases)
None 1
1 to 2 0.60 (0.49, 0.73) <0.001
3 or more 0.54 (0.43, 0.67) <0.001
Socio-economic status (IMDb quintiles)
Least deprived 1
2nd 1.13 (0.92, 1.37) 0.231
3rd 0.97 (0.79, 1.17) 0.734
4th 0.97 (0.75, 1.23) 0.809
Most deprived 0.85 (0.65, 1.08) 0.189
Missing 1.03 (0.87, 1.21) 0.741
aSample restricted to patients with at least 1 drug prescription. bIMD Index of Multiple Deprivation
Ble et al. BMC Geriatrics  (2015) 15:146 Page 6 of 10
increased HRM risk, largely due to NSAIDs and antiar-
rhythmic agents (digoxin, amiodarone and sotalol) pre-
scribing (data not shown).
Our methodology has some limitations. While most
chronic diseases have been shown to be reliably recorded
in CPRD [30] some question its validity [31]. Prescribing
data, the focus of this study, is deemed to be mostly accur-
ate as the issuing of scripts is computerised [31]. However,
we cannot completely eliminate the risk of limited under-
recording since a small proportion of scripts may be hand-
written. This might particularly affect the drugs prescribed
during home visits (e.g. antibiotics, pain killers etc.). An-
other limitation is that we were unable to code residential
status (even though the CPRD database includes people
living in nursing and residential home), which was previ-
ously associated with PIMs use [19, 20]. As mentioned,
due to the observational nature of the study residual con-
founding in some of the correlations found is also possible.
Finally, due to the fact that only a subset of high risk
medications has been considered, prescribing of HRM
could be underestimated.
While the Beers list is extensive, our analysis illustrated
that in the UK, HRM exposure was largely attributable to
ten drugs/drug classes. This includes sedatives, non-
steroidal anti-inflammatory drugs and anticholinergic
drugs which are captured in other prescribing optimisa-
tion tools such as START/STOPP [32], and hence some of
the identified modified Beers drugs are also prevalent his-
torically in the international literature [15]. Reducing or
optimising the use of the ten drugs/drug classes, particu-
larly NSAIDs, benzodiazepines and amitriptyline, could
dramatically reduce HRM in older patients, and particu-
larly those belonging to high-risk groups. That HRM pre-
scribing has not decreased over time requires careful
consideration. The reality of clinical practice is that it may
not always be feasible to avoid HRMs. As part of medical
Table 3 Logistic regression models for long-term HRM prescribing
Model 1 Model 2 Model 3
Sample size (unweighted)a 12,532 12,532 12,532
Weighted OR (95 % CI) p-value Weighted OR (95 % CI) p-value Weighted OR (95 % CI) p-value
Year sampled
2003/4 1 1 1
2007/8 0.82 (0.70, 0.96) 0.015 0.73 (0.61, 0.85) <0.001 0.73 (0.62, 0.86) <0.001
2011/12 0.74 (0.63, 0.87) 0.000 0.61 (0.51, 0.71) <0.001 0.61 (0.51, 0.72) <0.001
Age
65 to 84 years 1 1 1
85 years or over 1.26 (1.13, 1.39) 0.000 1.15 (1.03, 1.28) 0.009 1.16 (1.04, 1.28) 0.007
Sex
Men 1 1
Women 1.35 (1.17, 1.56) 0.000 1.40 (1.20, 1.62) <0.001 1.41 (1.20, 1.63) <0.001
Medications count (number of drugs)
1 1 1
2 to 4 2.27 (1.75, 2.93) <0.001 2.46 (1.91, 3.16) <0.001
5 to 9 4.71 (3.62, 6.12) <0.001 5.33 (4.08, 6.94) <0.001
10 or more 15.44 (10.0, 23.7) <0.001 17.77 (11.4, 27.5) <0.001
None 1
1 to 2 0.66 (0.49, 0.86) 0.003
3 or more 0.62 (0.46, 0.83) 0.001
Socio-economic status (IMDb quintiles)
Least deprived 1
2nd 1.11 (0.87, 1.41) 0.402
3rd 1.02 (0.79, 1.30) 0.886
4th 1.08 (0.82, 1.43) 0.569
Most deprived 1.07 (0.79, 1.42) 0.660
Missing 0.99 (0.80, 1.22) 0.953
aSample restricted to patients with at least 1 drug prescription. bIMD Index of Multiple Deprivation
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decision making, physicians may be driven to use higher
risk drugs, making a careful trade-off between attempts to
relieve symptoms directly affecting an older person’s qual-
ity of life, against the risk of future adverse consequences.
Consistent with this, four of the ten prevalent HRMs we
identified have strong sedative effects. Although UK in-
somnia management guidelines recommend cognitive and
behavioural interventions [33], the treatment of sleep dis-
orders, in cognitively intact and impaired people, might be
one of the key drivers of HRM resulting from an attempt
to manage this highly distressing condition.
Conclusions
HRMs rates for older people from UK general practices
participating to CPRD remain largely unchanged since
2003/4 against the backdrop of increasing polypharmacy.
Future research is needed exploring why HRM prescrib-
ing remains entrenched especially in the oldest old and
in women, and to support the development of targeted
interventions to improve prescribing safety.
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